|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:approves
|
gptkb:2007
gptkb:World_Health_Organization
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:can_be_combined_with
|
gptkb:artesunate
amodiaquine
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
first-line treatment
|
|
gptkbp:contraindication
|
severe liver disease
severe renal impairment
hypersensitivity to amodiaquine
|
|
gptkbp:developed_by
|
research institutions
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:drug_interactions
|
may affect blood levels of other drugs
may increase liver toxicity
|
|
gptkbp:duration
|
3 days
|
|
gptkbp:formulation
|
oral tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
artesunate-amodiaquine
|
|
gptkbp:interacts_with
|
other antimalarial drugs
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
high efficacy against P. falciparum
reduces malaria symptoms
shortens duration of illness
|
|
gptkbp:is_recommended_for
|
uncomplicated malaria
|
|
gptkbp:marketed_as
|
various brand names
|
|
gptkbp:mechanism_of_action
|
inhibits parasite growth
|
|
gptkbp:not_recommended_in_lactation
|
due to potential risks
|
|
gptkbp:not_recommended_in_pregnancy
|
due to potential risks
|
|
gptkbp:pharmacokinetics
|
excreted in urine
metabolized in liver
rapid absorption
|
|
gptkbp:provides_guidance_on
|
CDC guidelines
|
|
gptkbp:research_focus
|
long-term effects
combination therapies
resistance patterns
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:shelf_life
|
2 years
|
|
gptkbp:side_effect
|
gptkb:anemia
dizziness
fatigue
headache
nausea
vomiting
itching
skin rash
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:suitable_for
|
severe malaria
|
|
gptkbp:treatment
|
gptkb:artemisinin-based_combination_therapy
|
|
gptkbp:used_for
|
treatment of malaria
|
|
gptkbp:whoessential_medicines_list
|
included
|
|
gptkbp:bfsParent
|
gptkb:artemisinin-based_combination_therapies_(ACTs)
|
|
gptkbp:bfsLayer
|
8
|